Apitope, the drug discovery and development company, has posted positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis.
Patheon, a drug development and delivery solutions provider, has taken charge of a state-of-the-art manufacturing facility in Florence, South Carolina from Roche.
While food and beverage remain the largest sectors in terms of packaging machinery needs, no market can keep pace with the pharmaceutical growth forecast through 2020, according to the 2016 State of the Industry US Packaging Machinery Report.
Sarepta Therapeutics, a commercial-stage developer of innovative RNA-targeted therapeutics, has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV).
The UK pharmaceutical industry trade body, the Association of the British Pharmaceutical Industry (ABPI), has welcomed the Prime Minister’s speech on the Government’s negotiating objectives for exiting the EU.
The European Medicines Agency (EMA), in cooperation with the European Commission and the Member States of the European Union, is proposing changes to its existing guideline on first-in-human clinical trials, to further improve the safety of trial participants.
Swedish Orphan Biovitrum (Sobi) has entered into a 3-year agreement with Valeant Pharmaceuticals Ireland for the distribution of Ammonul injection in Europe, the Middle East and North Africa.
The first consignment of British manufactured medicines has been exported to Iraq by a new Yorkshire pharmaceuticals wholesaler and distributor set up to give Iraqi people access to high-quality treatments.
EyeGate has granted a subsidiary of Valeant Pharmaceuticals exclusive worldwide commercially and manufacturing rights to its EyeGate® II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients.
The US Food and Drug Administration (FDA) has accepted Novartis’ supplemental New Drug Application (sNDA) for filing, and granted Priority Review for the expanded use of Zykadia as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.